Abstract

This chapter presents a series of case studies and multiple choice questions and answers on the role of PET scans in lymphomas. It commences with a discourse on the evidence of extranodal disease leading to stage IV disease. One case study explains how one can recommend proceeding based on the PET-CT findings. Peripheral T-cell lymphomas (PTCLs) account for 10-15 percent of newly diagnosed non-Hodgkin's lymphoma. Changes in PET scans following therapy reflect the impact of the drugs on the cancer, and individual anticancer drugs such as rituximab do not, by themselves, affect the outcome of a PET scan. PET scans have been proposed as a way to determine if a residual mediastinal mass in a patient who has been treated for Hodgkin lymphoma represents active disease. The chapter further talks about relapse on subsequent follow-up.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley-Blackwell
Pages389-397
Number of pages9
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014

Keywords

  • Hodgkin lymphoma
  • Lymphomas
  • PET scans
  • PET-CT findings
  • Peripheral T-cell lymphomas (PTCLs)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Role of PET Scan in Lymphomas'. Together they form a unique fingerprint.

  • Cite this

    Lunning, M. A., & Armitage, J. O. (2014). Role of PET Scan in Lymphomas. In Cancer Consult: Expertise for Clinical Practice (pp. 389-397). Wiley-Blackwell. https://doi.org/10.1002/9781118589199.ch61